Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Langley

Showing results (311-320 of 345) with videos related to

Pageof 35
Sort By:
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2018
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune ResponseScott A Halperin, Joanne M Langley, Lingyun Ye, et al.
The Lancet. Infectious Diseases|May 14, 2021
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trialTimo Vesikari, Joanne M Langley, Nathan Segall, et al.
Lancet (London, England)|December 26, 2021
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialScott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al.
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
Human Vaccines & Immunotherapeutics|January 13, 2026
Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in CanadaTiffany Fitzpatrick, Jeanna Parsons Leigh, Rebecca Brundin-Mather, et al.
Pageof 35

Showing results (311-320 of 345) with videos related to

Sort By:
Pageof 35
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2018
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune ResponseScott A Halperin, Joanne M Langley, Lingyun Ye, et al.
The Lancet. Infectious Diseases|May 14, 2021
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trialTimo Vesikari, Joanne M Langley, Nathan Segall, et al.
Lancet (London, England)|December 26, 2021
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialScott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al.
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
Human Vaccines & Immunotherapeutics|January 13, 2026
Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in CanadaTiffany Fitzpatrick, Jeanna Parsons Leigh, Rebecca Brundin-Mather, et al.
Pageof 35